These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31197750)

  • 41. Long-term outcome of first 300 implanted Absorb bioresorbable vascular scaffolds in an all-comers Middle East population.
    Al Nooryani A; Elabbassi WN; AlBaba B; Kerfes JA; Abudaqa LM; Bhatia A; Abdelrahman NA; Boskovic N; Beleslin B
    J Int Med Res; 2019 Jan; 47(1):173-187. PubMed ID: 30235969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
    Ali ZA; Gao R; Kimura T; Onuma Y; Kereiakes DJ; Ellis SG; Chevalier B; Vu MT; Zhang Z; Simonton CA; Serruys PW; Stone GW
    Circulation; 2018 Jan; 137(5):464-479. PubMed ID: 29089314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold.
    Ng AK; Ng PY; Siu CW; Jim MH
    Cardiovasc Interv Ther; 2021 Oct; 36(4):462-469. PubMed ID: 33387354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: systematic review and meta-analysis of randomized clinical trials.
    Pavasini R; Serenelli M; Gallo F; Bugani G; Geraci S; Vicinelli P; Campo G
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S887-S897. PubMed ID: 28894594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients.
    Elias J; van Dongen IM; Kraak RP; Tijssen RYG; Claessen BEPM; Tijssen JGP; de Winter RJ; Piek JJ; Wykrzykowska JJ; Henriques JPS
    Neth Heart J; 2017 Jul; 25(7-8):429-438. PubMed ID: 28612280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two-year results from the German-Austrian ABSORB registry.
    Tröbs M; Achenbach S; Nef HM; Gori T; Naber C; Neumann T; Richardt G; Schmermund A; Wöhrle J; Zahn R; Hamm CW;
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E564-E570. PubMed ID: 34137482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-year clinical outcomes of the "Italian diffuse/multivessel disease absorb prospective registry" (IT-DISAPPEARS).
    De Carlo M; Testa L; Leoncini M; Nicolini E; Varbella F; Cortese B; Ribichini F; Bartorelli AL; Calabria P; Indolfi C; Tomai F; Loi B; Fischietti D; Tarantini G; Bedogni F; Petronio AS
    Int J Cardiol; 2019 Sep; 290():21-26. PubMed ID: 31104821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
    Kereiakes DJ; Ellis SG; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; Tan SH; Ediebah DE; Simonton C; Stone GW;
    Circulation; 2019 Dec; 140(23):1895-1903. PubMed ID: 31553222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):813-824. PubMed ID: 31730255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry.
    Cayla G; Koning R; Fajadet J; Sainsous J; Carrié D; Elhadad S; Tarragano F; Lefévre T; Ranc S; Ghostine S; Garot P; Marco F; Maillard L; Motreff P; Le Breton H;
    Arch Cardiovasc Dis; 2019 Feb; 112(2):113-123. PubMed ID: 30630761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.